Aplindore

Aplindore

Systematic (IUPAC) name
(2S)-2-[(phenylmethylamino)methyl]-2,3,7,9-tetrahydro-[1,4]dioxino[3,2-e]indol-8-one
Identifiers
CAS Number	189681-71-8 Y
ATC code	none
PubChem	CID: 6440763
ChemSpider	139676 Y
UNII	Q5O76TA0ML Y
KEGG	D03214 Y
ChEMBL	CHEMBL2110659 N
Chemical data
Formula	C18H18N2O3
Molecular mass	310.346 g/mol
SMILES c4ccccc4CNCC(CO2)Oc1c2ccc(N3)c1CC3=O
InChI InChI=1S/C18H18N2O3/c21-17-8-14-15(20-17)6-7-16-18(14)23-13(11-22-16)10-19-9-12-4-2-1-3-5-12/h1-7,13,19H,8-11H2,(H,20,21)/t13-/m0/s1 Y Key:DYJIKHYBKVODAC-ZDUSSCGKSA-N Y
NY (what is this?)  (verify)

Aplindore (DAB-452) is a drug which acts as a partial agonist selective for the dopamine receptor D2. It is being developed by the pharmaceutical company Neurogen as a treatment for Parkinson's disease and restless legs syndrome.

On December 23rd 2009 Neurogen was acquired by Ligand Pharmaceuticals. Rights to Aplindore were given to Ligand around time of merger. As of 2008, Phase II was completed and Ligand.

Upon reviewing company website (Ligand.com) this drug is currently not listed at the moment due to several programs already partnered with GSK. GSK holds a significant share of the drug RLS drug programs on the market with Requip XR and the recent FDA approval of Horizant. To prevent any direct competition and losing strong ties with GSK, Aplindore is not listed at the moment on Lidgand website. If this medication were to reach phase III, this could adversely effect Ligand`s portfolio of partnered and unpartnered assets. By electing not to list the drug on company website, Ligand maintains the appearance that they are "currently actively seeking a partner" when a potential investor inquirers about drug development via email.